In this episode, David Flores delves into the fascinating realm of psilocybin cultivation, innovation, and exploration with the co-founding managing partners of Rose Hill, a pioneering company based in Jamaica.
Similar Posts
Interview with James Lanthier, CEO of Mindset Pharma
In our conversation, James goes into detail about Mindset’s new lead drug candidate MSP-1014, when the company expects to take the drug to clinical trials, and why next generation drugs are an important commercial opportunity for anyone looking to invest in the psychedelic sector.
MindMed Facing Competition From HAVN? Plus Financials and Phase 2 Trials (MNMD, CYBIN, HAVN, MYCO)
Hey guys! In this week’s industry specific news, we’ll cover some interesting developments for MindMed, Mydecine, Cybin, HAVN, and a private company called WAKE. One of the biggest highlights is that HAVN might enter in direct competition with MindMed by penetrating the cluster headaches market. Stay tuned till the end the hear more on this specific news!
Timestamps:
0:00 – Intro
1:00 – MindMed Begins a Mescaline Study
4:35 – MindMed & The Chopra Foundation
8:30 – Cybin Progresses Phase 2a psilocybin study
11:56 – Mydecine announces Q1 Financials
14:16 – Havn Life Sciences enters the Cluster Headaches Game
16:30 – Wake Receives First-Ever Approval for Psilocybin for Anxiety & Depression
Enjoy!
Links:
MindMed (MNMD/ MMED / MMQ)) Begins a Mescaline Study:
https://mindmed.co/news/press-release/mindmed-announces-the-approval-of-mescaline-study/
MindMed Partners Up with The Chopra foundation:
https://mindmed.co/news/press-release/the-chopra-foundation-and-mindmed-enter-into-letter-of-intent-to-partner-on-the-future-of-psychedelic-medicines-mental-wellbeing/
Cybin (CYBN) Progresses Phase IIa psilocybin film strip study:
https://www.clinicaltrialsarena.com/news/cybin-phase-ii-psilocybin/
Mydecine (MYCO / MYCOF) Q1 Financials:
https://psilocybinalpha.com/news/mydecine-reports-first-quarter-2021-financial-results-and-provides-business-update
Havn Life Sciences (HAVN/ HAVLF/ 5NP) Begins to Study Cluster Headaches
https://havnlife.com/havn-life-enters-into-agreement-to-acquire-clinical-stage-ip-for-development-of-lsd-derived-api-for-cluster-headaches/
Wake Receives First-Ever Approval for Psilocybin Microdose Study for Anxiety and Depression
https://psychedelicspotlight.com/wake-psilocybin-microdose-study/
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video editing: @themyaholy
https://benzinga.grsm.io/jameshallifa…
https://benzinga.grsm.io/thepsychedel…
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PsychedelicStocks #HAVN
MindMed’s Patent STRATEGY & WHY Haven’t We Covered It YET? (MMED/ MNMD)
MindMed’s Patent STRATEGY & WHY Haven’t We Covered It YET? (MMED/ MNMD)
Patents and IP are important because it allows companies to protect their innovations and re-coup sunk costs into research and development by giving them a set period of time that only they can profit from any inventions they developed.
Given the importance of patents, some people have reached out and have asked why I haven’t talked about MindMed’ patents more.
For example, if you go to their Investors deck, you will see that MindMed, (MMED: NEO), (MNMD : NASDAQ), has 45+ different patent applications. We definitely haven’t done 45 videos on the matter. And that is because we actually don’t know what most of these patent applications are!
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#mindmed #mmed #mnmdstock
Are Celebrities Helping the Psychedelic Movement?
To watch the entire Spotlight In Focus episode, visit: https://www.altrd.tv/shows/spotlight-focus/season/1/episode/2…
Psilocybin as an Agent for Human and Cultural Development with Jahan Khamsehzadeh Ph.D.
In this episode, Dr. Khamsehzadeh delves into our historical and ancestral relationship to psilocybin and theorizes how mushrooms have impacted the development of the brain.
MindMed CEO AMA: 18-MC Patent, Digital Tech, LSD Trials and More! (MNMD / MMED)
In today’s episode, James from PSYCBiz interviews Robert Barrow, CEO…